Intralesional injection of the calcium channel blocker Verapamil in Peyronie's disease: A critical review.

To assess the effectiveness of an intralesional injection of verapamil in men with Peyronie's disease (PD).

The data provided in the current review are based on a thorough review of the available original articles on PD retrieved with a systematic literature search using PubMed- Medline, and the Cochrane Central Register of Controlled Trials, up to December 2019, to identify studies dealing with Peyronie's disease and its treatment. Included were only original articles, that we thoroughly evaluated. We searched for the primary and secondary terms of: "Peyronie's disease," "Penile curvature," "Erectile dysfunction," "Verapamil and Peyronie's disease," "Calcium channel blocker," and "Intralesional injection."

The initial search of the databases yielded a total of 1240 studies (PubMed: 1058; Cochrane: 182), as of December 2019. Seventy studies were removed due to duplication. Further 986 studies were removed due to not being in English (except for one study by Arena F. for which we got a translation form Italian), being about animal experimentations, not being full-text, and not being clinical trials. Likewise, studies not referring at all to verapamil were excluded (148). From the remaining 36 full-text articles we focused on 13 studies which met the inclusion criteria, mainly being deemed relevant to the context of this study.

Calcium channel blockers have been shown in both in vitro and in vivo studies to inhibit the synthesis and secretion of extracellular matrix molecules, as well as to increase collagenase activity. Patients with localised plaque are the best candidates for intralesional injections of verapamil. The beneficial effects of intralesional verapamil are apparent within the first three months. For patients who respond to treatment, the injections should be continued for six months. Patients who fail to respond to intralesional verapamil or whose angulation is greater than 30° at presentation should be considered candidates for surgery. Injection of verapamil is clinically safe for patients with Peyronie's disease, and it appears to induce a rapid, beneficial effect in patients for the reduction of plaque size. Intralesional verapamil injection for Peyronie's disease could reduce pain, decrease penile curvature, and improve sexual function.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2020 Oct 02*** epublish ***

Murad Asali, Muhammad Asali

Assuta Medical Center, Ben Gurion University of the Negev, Beer Sheva. .

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Annual Virtual Meeting / Oct 17
  • 2020 Annual Congress / October 10 - 11
  • 2020 Annual Meeting / October 1-3
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland